CSE’s Barrington Miller catches up with Timothy Ko, CEO of Entheon Biomedical Corp. (CSE:ENBI) to discuss how his company is pursuing R&D of DMT-based products to safely treat addiction. Timothy provides an update on what the company has accomplished in the year since they’ve been public and upcoming plans for clinical trials.
Here’s an overview of what Barrington and Timothy cover in this edition of the “Exchange for Entrepreneurs” podcast:
0:00 – Catching up with Timothy Ko and Entheon Biomedical
2:30 – What has happened since they listed on the CSE – Canadian Securities Exchange
4:12 – Personalization through genetics
6:20 – The genetics test kit
8:30 – Pathway for clinical trials
9:55 – What’s coming next for investors
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
Learn more about Entheon Biomedical Corp. at Entheon Biomedical Corp. | CSE – Canadian Securities Exchange (thecse.com)